Bone Biologics Corp (BBLG) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Per the Roarable RQD rating, BBLG scores 46 out of 100, a letter grade of D, labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars break down as follows. Fundamental Cash Engine scores 8 of 20, reflecting ROIC of -35% and an FCF yield of 0%. Whale 13F Flow scores 13 of 20, reflecting institutional accumulation and options positioning. Insider Conviction scores 5 of 20, reflecting SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 10 of 20, reflecting Beta of 1.0 and sector sensitivity. Forensic Balance Sheet scores 10 of 20, reflecting Altman Z of 2.5, Piotroski F of 3/9, and Debt/Equity of 0.5.

For a prospective investor, the weakest pillars are the cash engine and insider conviction, which together point to a business not yet generating returns on capital and insiders not signaling confidence. The whale flow pillar is the strongest relative score, which suggests some institutional interest, though the rating treats it as a partial offset rather than a driver. The forensic and macro pillars are mid-range. The practical takeaway is that upside would require a clear improvement in cash generation, which the source data does not show, and the stock's price of $0.38 against a 52-week range of $0.36 - $2.39 indicates the market has already marked the shares sharply lower. Any valuation discussion here is limited to what the source provides; no forward multiples are available to frame a fair-value comparison.

Bone Biologics Corp (BBLG) is a NASDAQ-listed issuer classified in the Health Care sector and the Industrial Specialties industry, per the company profile. The profile does not describe its products, customers, or revenue model. Per the SEC financials, reported revenue is $0.0M in each listed fiscal year, so the source data does not show a revenue-generating operation. Not available in source data for the remaining business details.

Per the SEC financials, the company reported operating and net losses in all three periods, with losses narrowing from $-8.9M in FY 2023 to $-3.1M in FY 2025, and free cash flow negative in each year. Per the market data, gross, operating, and net margins are each 0% and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3 of 9, and Debt/Equity is 0.5. Cash and debt balances are N/A in the SEC financials, so the balance sheet posture cannot be fully characterized from the source data.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE and no butterfly links are recorded. The source data therefore identifies no upstream suppliers, downstream customers, or sector-correlated peers. For an investor, the absence of mapped dependencies means second-order ripples cannot be assessed from this dataset. The watch item is the going-concern language in the news feed, since a financing event or liquidity constraint would be the most direct second-order transmission channel, but the source does not specify the financing terms or timing.

• What are the company's cash and debt balances, since both are N/A in the SEC financials despite a $6.09M cash reference in the news feed?
• What is the nature and timing of the going-concern doubt, and what financing or liquidity plans does the source describe?
• What products or services generate the company's activity, given revenue is reported as $0.0M in every period?
• Who are the institutional and insider holders behind the whale and insider pillar scores?
• What drives the Q3 "loss narrows" result, and how does it reconcile with the full-year figures?